Protalix Biotherapeutics, Inc. (PLX) Announces Closing of Public Offering and Exercise of Over-Allotment Option
2/23/2012 9:51:58 AM
CARMIEL, Israel, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), announced today the closing of its previously announced underwritten public offering. Prior to the closing, the underwriters exercised, in full, their over-allotment option to purchase an additional 675,000 shares of common stock. As a result, the Company sold a total of 5,175,000 shares of its common stock at a price to the public of $5.25 per share. After underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately $25.4 million. The shares were sold pursuant to the Company's existing shelf registration statement, the prospectus contained therein and the prospectus supplement filed with the U.S. Securities Exchange Commission, or the SEC, on February 16, 2012.
comments powered by